Status:
COMPLETED
A Longitudinal, Observational Biomarker Study in Pancreatic Cancer Patients Receiving Chemotherapy
Lead Sponsor:
National Cancer Center, Korea
Conditions:
Pancreatic Cancer
Eligibility:
All Genders
Brief Summary
1. Based on the literature, the pancreatic cancer treatment predictor biomarker, which is used in the domestic clinical field, is actually applied to the pancreatic cancer patient cohort of the Nation...
Detailed Description
1. Immunohistochemistry and gene test for hENT1, DCK, SMAD4, CES2, BRCA 1/2,PALB2, MMRd, MSI, Tumor Ag and etc. on Cancer sample 2. Collect data of Biomarker for pancreatic cancer 3. Compare with Big ...
Eligibility Criteria
Inclusion
- Pathologically Confirmed Pancreatic Cancer Patients
Exclusion
- Subjects who do not agree with the study
Key Trial Info
Start Date :
April 3 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2023
Estimated Enrollment :
238 Patients enrolled
Trial Details
Trial ID
NCT04281511
Start Date
April 3 2019
End Date
September 30 2023
Last Update
November 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NATIONAL CANCER CENTER 323, Ilsan-ro, Ilsandong-gu,
Goyang-si, Gyeonggi-do, South Korea, 10408